Risedronate is a bisphosphonate which also includes the drugs alendronate prescribed for the treatment of Paget's disease of bone (a disease in which the formation of bone is abnormal) and in persons ...

Author(s)Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, ...

Please provide your email address to receive an email when new articles are posted on . Adults with a history of glucocorticoid-induced osteoporosis assigned to therapy with the monoclonal antibody ...

Please provide your email address to receive an email when new articles are posted on . Older adults who stop using risedronate after at least 5 years of treatment have an increased mortality risk ...

The rate of nonvertebral fractures in patients with osteoporosis increases with age. Bisphosphonates are the most common therapy for osteoporosis; randomized controlled trials have shown that ...

Review the side-effects of Risedronate as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

All studies were conducted after receiving approval from the Institutional Review Board of the Graduate School of Medical Science, Kanazawa University. This prospective observational study was ...

May 20, 2003 — Compared with alendronate (Fosamax), risedronate (Actonel) is associated with fewer clinically severe adverse gastrointestinal (GI) events in the elderly, according to the results of ...

Any pause in taking the osteoporosis drug risedronate (Actonel) should last no longer than 2 years rather than the 2 to 3 years currently recommended for bisphosphonates, new research suggests. In a ...

Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis The June 1, 2008, article by ...